What you eat — and don’t eat — affects your retina. Decades of research, particularly the large AREDS and AREDS2 studies, have shown that the right vitamins and minerals can slow the progression of age-related macular degeneration (AMD) by about 25%. Diet, smoking, blood pressure, blood sugar and weight all matter. This article tells you what really makes a difference, and what doesn’t.

What Is AREDS2?

AREDS2 stands for the Age-Related Eye Disease Study 2 — a landmark American study that tested specific vitamin and mineral combinations in patients with AMD. The formula that came out of that study is now the standard supplement recommendation worldwide for intermediate and advanced AMD.

Important things to know about AREDS2

• It is for intermediate or advanced AMD in at least one eye — not for healthy eyes or very early AMD.
• It slows progression by about 25%; it does not cure or reverse AMD.
• The original AREDS used beta-carotene, which increased lung cancer risk in smokers. AREDS2 replaced it with lutein and zeaxanthin, which are safe for smokers.
• It does not help diabetic retinopathy, glaucoma or general “tiredness of the eyes”.
• It is taken as 1 or 2 tablets a day, lifelong, with food.

Foods That Help Your Retina

For most patients, food is more important than tablets. Three groups of nutrients matter most:

1. Lutein and zeaxanthin — the macular pigment

These yellow plant pigments collect specifically in the macula, where they filter blue light and act as antioxidants. Foods rich in lutein and zeaxanthin:

• Spinach (palak)
• Methi (fenugreek leaves), amaranth (laal saag), drumstick leaves
• Kale, broccoli, peas
• Sweet corn, orange/yellow capsicum
• Egg yolk

2. Omega-3 fatty acids — for membranes and inflammation

The photoreceptors in your retina are unusually rich in omega-3 (DHA). Eat these regularly:

• Fish — mackerel (bangda), sardines, salmon, hilsa, pomfret — 2–3 times a week if you eat fish
• Walnuts (akhrot), almonds
• Flaxseed (alsi), chia seeds
• If vegetarian, an algae-based DHA supplement is reasonable.

3. Antioxidants — to neutralise oxidative stress

• Vitamin C — amla, citrus fruit, guava, peppers
• Vitamin E — sunflower seeds, almonds, vegetable oils
• Zinc — pulses, whole grains, dairy, meat
• Carotenes — carrots, sweet potatoes, mango, papaya, pumpkin

What Hurts Your Retina

1. Smoking

Smoking doubles the risk of AMD. It also worsens diabetic retinopathy, vein occlusions and central serous chorioretinopathy. There is no safe level of smoking for the eye. Stopping at any age helps; the risk falls noticeably within 5 years and continues to fall thereafter.

2. Uncontrolled diabetes, high blood pressure and cholesterol

The vessels of the retina are tiny and exquisitely sensitive to systemic illness. Tight control of these three is the most powerful daily action you can take for retinal health.

3. Excess UV light

Long-term sun exposure may contribute to AMD. Wear UV-blocking sunglasses outdoors in strong sunlight, and a hat with a brim.

4. Excess weight and inactivity

Obesity is associated with progression of AMD. Regular moderate exercise — even 30 minutes walking, 5 days a week — helps.

5. Unsupervised steroids (any form)

Steroid creams, inhalers, joint injections and Ayurvedic/herbal preparations that hide steroid content can trigger CSCR. Always tell us every medicine you are taking, including over-the-counter products.

Who Should Take AREDS2?

Common Mistakes Patients Make

• Taking a generic “eye vitamin” — check it contains the actual AREDS2 doses, not a token amount.
• Stopping AREDS2 after a few months — it must be taken long-term.
• Taking multiple supplements with overlapping ingredients — excess zinc, vitamin A or iron can be harmful.
• Relying on supplements while continuing to smoke or skip diabetic control.
• Believing AREDS2 helps glaucoma or diabetic eye disease — it does not.

Brands and Costs

Several well-known brands sell AREDS2-formulation tablets in India. We will recommend a specific brand based on availability and cost in Nagpur. Always check the label for:

• Lutein 10 mg + Zeaxanthin 2 mg
• Vitamin C 500 mg
• Vitamin E 400 IU
• Zinc 80 mg (or 25 mg in lower-zinc AREDS2 formulations)
• Copper 2 mg

What About Other Supplements?

• Omega-3 capsules — the AREDS2 study did not show benefit from omega-3 supplements over and above the core AREDS2 formula. Eating omega-3-rich foods is still recommended.
• Saffron, bilberry, ginkgo — some interesting small studies; no proven benefit yet.
• “Eye drops with vitamins” — do not penetrate the eye and have no proven role in macular health.
• Beta-carotene — avoid if you smoke or used to smoke.

Retinal laser is one of the oldest and still one of the most useful treatments in our specialty. It uses a precise beam of light to seal leaking vessels, close abnormal new vessels, or strengthen the retina at risk of tearing. Modern laser is gentler, more targeted and far better tolerated than the lasers of 20 years ago. At Suraj Eye Institute, we use four different laser modalities, each chosen for a specific purpose.

The Four Main Types of Retinal Laser

1. Pan-Retinal Photocoagulation (PRP)

The classical “scatter” laser. Hundreds of small spots are placed across the peripheral retina, sparing the macula and optic disc. By treating the oxygen-starved peripheral retina, PRP reduces the body’s call for new blood vessels, causing them to shrink. Used for:

• Proliferative diabetic retinopathy
• Ischaemic retinal vein occlusions with new vessels
• Other ischaemic retinopathies (sickle cell, Eales’)
• Prevention of neovascular glaucoma

2. Focal / Grid Laser

Small, targeted spots placed near the macula to seal individual leaking microaneurysms (focal) or to cover an area of diffuse leakage in a grid pattern. Used for:

• Non-centre-involved diabetic macular edema
• Macular oedema from BRVO (in selected cases)
• Sealing extrafoveal leak points in CSCR

3. Micropulse / Subthreshold Laser

A modern, gentler laser that delivers the energy in tiny pulses, stimulating the retinal cells without leaving a visible burn. It avoids the scarring of older lasers. Used for:

• Chronic CSCR
• Centre-involving DME (as add-on therapy)
• Macular oedema from BRVO
• Selected cases of dry AMD trials

4. Photodynamic Therapy (PDT)

A two-step treatment: a light-sensitive drug (verteporfin) is given by intravenous drip and accumulates in abnormal vessels; a special low-power laser is then applied to the lesion, activating the drug only where it has settled. The abnormal vessels close while normal retinal vessels are spared. Used for:

• Polypoidal choroidal vasculopathy (PCV) — particularly effective
• Chronic central serous chorioretinopathy (CSCR)
• Some choroidal tumours and selected wet AMD cases

How a Laser Visit Works

• You arrive, have a check of vision and eye pressure, then drops to dilate the pupil.
• You sit at the laser machine, similar to an OCT setup.
• An anaesthetic drop is given. A contact lens may be placed on the cornea with a clear gel.
• The doctor focuses the laser and delivers the spots while you fixate.
• You may see bright flashes and feel a mild dull ache — especially in PRP, sometimes none in focal or micropulse.
• A typical PRP session takes 10–20 minutes; focal laser 5–10 minutes.
• After the laser, your vision will be blurry for a few hours from the dilating drops; arrange someone to bring you home.

What to Expect After Laser

• Vision improves slowly — weeks to months. The goal is usually to preserve, not regain, vision.
• Mild bruising on the white of the eye or eyelid is occasional and harmless.
• Side vision may be slightly reduced after extensive PRP — especially night vision.
• Multiple sessions may be needed, particularly for PRP.
• OCT and OCTA at follow-up visits track treatment response.

Possible Side Effects

• Temporary blurring after the session
• A small ache for a few hours (more common with PRP)
• Reduced night vision or reduced peripheral vision after extensive PRP
• Rarely, a small choroidal effusion or transient pressure rise
• Rarely, scarring close to the macula (avoided with modern focal/micropulse techniques)

How Laser Compares with Injections

For many patients, modern care combines laser and injections in a tailored plan.

OCT (Optical Coherence Tomography) and its newer sibling OCT-Angiography (OCTA) are two of the most powerful tools we have to look at the retina. They are non-contact, painless, dye-free scans — and together they let us see both the structure and the circulation of the retina in seconds. Almost every patient who visits our retina clinic gets at least one of these scans.

What OCT Shows

A standard OCT scan produces two kinds of images:

• A cross-section (“B-scan”) — a slice through the retina, like a CT slice. We can see all the layers separately, measure thickness, and detect fluid, deposits or scars.
• A thickness map (“en-face”) — a colour-coded map of the macula’s thickness, useful for tracking change over time.

What OCT-Angiography (OCTA) Shows

OCT-Angiography uses the same machine, but a different scanning pattern. By taking multiple scans of the same spot a fraction of a second apart, the computer detects motion — and the only thing that moves inside the retina is blood. The software then maps these moving signals into a picture of the blood vessels — without any dye injection.

• Shows the retinal capillary network in two layers (superficial and deep)
• Shows the choriocapillaris behind the retina
• Detects abnormal new vessels (CNV) without any dye
• Maps the foveal avascular zone (FAZ) — enlarged in diabetic retinopathy
• Identifies areas of poor blood flow in diabetes, vein occlusions, sickle cell disease

OCT vs. OCTA vs. Fluorescein Angiography

What Conditions Are Diagnosed and Followed with OCT/OCTA?

• Diabetic retinopathy and diabetic macular edema
• Age-related macular degeneration (dry and wet)
• Polypoidal choroidal vasculopathy (PCV)
• Retinal vein occlusion (CRVO and BRVO)
• Central serous chorioretinopathy (CSCR)
• Glaucoma — nerve fibre and ganglion cell layer measurements
• Macular hole, epiretinal membrane, vitreomacular traction
• High myopia and myopic CNV
• Choroidal nevus and tumours (selected cases)
• Optic nerve disorders

The Patient Experience

What to expect during the scan

• You sit at the machine and rest your chin on a support.
• You look at a fixation target inside the machine.
• A faint red or green light beam scans your eye for a few seconds.
• The procedure is completely painless.
• Eye drops to dilate the pupil are usually not necessary, though sometimes used.
• Total time at the OCT machine: about 5–10 minutes for both eyes.

Limitations to know about

• OCT cannot see through a dense cataract or severe vitreous haemorrhage.
• OCTA does not show leakage — FA is still needed for some questions.
• Movement during the scan can blur the image; we may repeat it if needed.
• OCTA covers a smaller field of view than ultra-widefield FA.

Why We Use Both OCT and OCTA

Each scan gives information the other cannot:

• OCT tells us where and how much fluid is present, and how the layers are organised.
• OCTA tells us where the abnormal vessels are and where blood flow is poor.
• Together, they give the full picture of a disease in seconds, without any dye injection.

Anti-VEGF injections are the single most important advance in retinal medicine in the last 25 years. They are small injections of medicine given into the eye to control leaky and abnormal blood vessels at the retina. Conditions that used to cause irreversible blindness — wet AMD, diabetic macular edema, retinal vein occlusion, PCV — are now controllable, often for many years, with these injections.

What Conditions Are Treated?

• Wet age-related macular degeneration (Wet AMD)
• Diabetic macular edema (DME)
• Proliferative diabetic retinopathy (PDR)
• Retinal vein occlusions (CRVO and BRVO) with macular swelling
• Polypoidal choroidal vasculopathy (PCV)
• Myopic choroidal neovascularisation (myopic CNV)
• Choroidal neovascular membranes from any cause
• Retinopathy of prematurity (ROP) in selected cases
• Neovascular glaucoma as part of combined management

How the Injection Is Given

What happens at your injection visit

• You arrive: vision is checked, eye pressure measured, OCT done if needed.
• Anaesthetic drops are placed in the eye to numb it.
• The eye is cleaned with antiseptic (povidone-iodine) and a sterile drape is applied.
• The injection itself takes 3–5 seconds. Most patients feel a small pressure, not sharp pain.
• You blink, the drape is removed, and the eye is washed.
• You rest briefly; the eye pressure and vision are re-checked.
• You go home the same day. Total visit usually under 60–90 minutes.

The Anti-VEGF Drugs We Use

The choice depends on your condition, response, eye anatomy, and cost. We will discuss the options with you.

How Many Injections Will I Need?

Most diseases follow a “loading then maintenance” pattern:

• Loading phase — typically 3 monthly injections to dry the retina.
• Maintenance phase — based on monthly OCT response, the interval is gradually extended (treat-and-extend) or fixed monthly.
• Year 1 typically needs 5–7 injections in DME and wet AMD.
• Subsequent years usually require fewer injections, sometimes none in some patients.
• Some patients can be tapered off entirely; others need long-term maintenance.

Side Effects and Safety

Common, expected, mild

• Mild redness at the injection site for a day or two
• A small subconjunctival haemorrhage (a red patch on the white of the eye) — harmless
• Brief gritty sensation, mild watering
• Small black floaters from the drug for a few hours after injection

Rare but important

• Infection inside the eye (endophthalmitis) — very rare (around 1 in 2,000–5,000 injections) but a serious emergency. Sudden severe pain, redness or drop in vision in the days after an injection must be reported the same day.
• Retinal detachment or tear — very rare.
• Inflammation inside the eye (mild iritis) — uncommon, treated with drops.
• Rise in eye pressure — usually transient.
• Systemic side effects — the dose used in the eye is very small. Theoretical risks of stroke or cardiovascular events are extremely low.

What to Do After the Injection

• You can read, watch TV, eat normally the same evening.
• Avoid rubbing or pressing the eye.
• Avoid swimming, dusty environments and eye make-up for 2–3 days.
• Use prescribed antibiotic drops if given.
• Small floaters from the drug usually settle within a day.
• If pain or vision worsens, come the same day.

How We Track Your Response

Every visit usually includes OCT — the most sensitive way to see if fluid is going down. We compare your current OCT to your previous scans and decide:

• If the macula is drying nicely, we may extend your next interval (treat-and-extend).
• If fluid persists, we may switch drugs or add steroid, PDT or laser.
• Vision is also tested at each visit, but the OCT often shows changes first.

Central Serous Chorioretinopathy — usually shortened to CSCR or just “CSR” — is a condition where clear fluid collects under the central retina, lifting the macula off its normal seat. Vision becomes blurred, dimmer, slightly smaller and often distorted. CSCR is most common in working-age men under stress, particularly those who have recently taken steroids in any form.

What Happens Inside the Eye

The retina sits on a layer called the Retinal Pigment Epithelium (RPE), which acts as a pump — constantly removing fluid from beneath the retina. In CSCR, the choroid (the blood-vessel layer behind the retina) becomes congested and leaky, and small breaks in the RPE allow fluid to seep in. The result is a blister of clear fluid under the macula, which lifts the photoreceptors away from their normal nourishment.

Symptoms

• Sudden mild-to-moderate blur of central vision in one eye
• A central or paracentral grey/darker spot
• Objects look smaller (micropsia) or distorted
• Colours look slightly faded or yellower
• Difficulty reading or focusing on detailed work
• Vision often worse in the morning and slightly better through the day (as the body absorbs some fluid)
• Usually painless and one-eyed; the other eye can be affected later

Who Gets CSCR?

• Men aged 25–55 (about 4–6 times more common than in women)
• Type-A personality, high-stress occupations — the classic “stressed executive” pattern
• Recent steroid use in any form — oral, injection, inhaler, nasal spray, skin cream, or even some Ayurvedic / herbal preparations that secretly contain steroids
• Pregnancy (usually resolves after delivery)
• Cushing’s syndrome and other states of high cortisol
• Sleep disorders, obstructive sleep apnoea
• Helicobacter pylori infection (a weaker association)
• Family history in some cases

How We Diagnose CSCR

• Dilated retinal examination — the macula appears subtly elevated with a dome of clear fluid
• OCT — the cornerstone test. Shows the subretinal fluid pocket and the thickened (pachy-) choroid
• Fundus autofluorescence (FAF) — shows the trail of past leaks and damaged RPE in chronic cases
• Fluorescein angiography — classically shows a “smokestack” or “inkblot” leak point
• ICG Angiography — shows choroidal vessel dilation and helps rule out polypoidal disease (PCV)
• OCT-Angiography — checks for any new vessels in long-standing cases

Types of CSCR

• Acute CSCR — first or single episode lasting weeks to a few months. Most cases resolve spontaneously.
• Recurrent CSCR — episodes recur in the same or the other eye.
• Chronic CSCR — fluid persists beyond 4–6 months, with widespread RPE changes. Vision recovery is harder.
• Bullous / atypical CSCR — rare severe forms, often associated with strong steroid exposure.

Treatment Options

• Stop the trigger first — identify and remove any source of steroid. Treat stress, sleep apnoea and Helicobacter where relevant.
• Observation or focal laser — for first-episode acute CSCR, with monthly OCT monitoring. About 80% of cases resolve in 3–4 months on their own — but allowing fluid to sit on the macula for many months can cause permanent foveal changes. At Suraj Eye Institute, when fluorescein angiography shows a clearly identified extrafoveal leak point, we prefer to seal the leak with a focal laser rather than wait.
• Lifestyle measures — adequate sleep, stress reduction, breathing or meditation practice, regular exercise.
• Photodynamic Therapy (PDT) — reduced-fluence “safety” PDT is currently the most effective treatment for persistent or chronic CSCR.
• Micropulse / subthreshold laser — a gentler laser used for chronic CSCR when PDT is not available or appropriate.
• Oral medication in selected cases — mineralocorticoid receptor antagonists (eplerenone, spironolactone) are used in some patients.
• Anti-VEGF injections — only if secondary new vessels (CNV) develop in chronic cases.

What to Expect from Treatment

• Acute CSCR has an excellent prognosis: vision usually returns close to baseline.
• Some patients are left with a mild residual change in colour vision or contrast.
• Chronic / recurrent CSCR may leave permanent macular changes — treatment is aimed at preventing further damage.
• About 30–50% of patients have a recurrence at some point. Long-term lifestyle changes reduce this risk.

Self-Care

• Stop all steroids wherever it is safely possible, in discussion with the prescribing doctor.
• Sleep 7–8 hours, treat any sleep apnoea.
• Reduce work stress — consider yoga, meditation, regular exercise.
• Limit caffeine, alcohol and smoking.
• Manage blood pressure and obesity.
• Amsler grid weekly to detect recurrence.

When to Come to Us

A new or worsening blur, a fresh dark patch, or recurrence of symptoms after a previous episode — come for an OCT-based evaluation.

Retinal Vein Occlusion is a “blockage” in one of the small veins that drain blood out of the retina. When the vein is blocked, blood and fluid back up, causing sudden blurring, swelling and bleeding inside the eye. It is one of the most common vascular emergencies of the retina and the second-leading cause of vision loss from retinal vascular disease, after diabetic retinopathy.

What Happens Inside the Eye

Each retina is drained by a network of small veins that come together to form the central retinal vein at the optic nerve. If a vein becomes narrowed by an artery pressing against it (often at a crossing point), a clot can form and block flow. Blood backs up behind the block, leading to:

• Haemorrhages spreading across the retina
• Swelling of the macula (macular edema)
• Lack of oxygen in the affected area
• In severe cases, growth of abnormal new vessels and a dangerous form of glaucoma

The Two Main Types

• Branch Retinal Vein Occlusion (BRVO) — a smaller, sector-supplying vein is blocked. Bleeding and swelling are limited to one quadrant of the retina. Vision is affected only if the macula is involved.
• Central Retinal Vein Occlusion (CRVO) — the main central vein is blocked at the optic nerve. The entire retina is affected. Vision drops dramatically and more severely.
• Hemiretinal Vein Occlusion (HRVO) — a less common variant where the upper or lower half of the retina is involved.

Symptoms

• Sudden, painless drop in vision in one eye — often noticed on waking up
• A dark patch or shadow over part of the vision
• Distortion of straight lines
• Floaters (if there is associated vitreous bleed)
• Rarely, deep aching pain weeks later if neovascular glaucoma develops

Who Is at Risk?

• High blood pressure — by far the most common association
• Diabetes mellitus
• High cholesterol or atherosclerosis
• Glaucoma — high eye pressure compresses veins at the optic nerve
• Smoking
• Obstructive sleep apnoea
• Inflammatory or clotting disorders (in younger patients)
• Oral contraceptives, hormone replacement therapy
• Age above 50 (most cases), though younger patients can be affected

How We Diagnose RVO

• Dilated retinal examination — the diagnosis is usually obvious on fundus examination
• OCT — measures macular swelling and follows treatment response
• OCT-Angiography — non-invasively maps areas of poor blood flow (non-perfusion)
• Fluorescein angiography — the most detailed map of the non-perfusion zones and any new vessels
• Ultra-widefield fundus imaging — valuable for following large peripheral non-perfusion
• Systemic workup — BP, blood sugar, lipids, kidney function; in selected patients, sleep study or clotting profile

Treatment Options

• Intravitreal anti-VEGF injections — the first-line treatment for the macular swelling that causes vision loss in both CRVO and BRVO. Aflibercept, Ranibizumab, Brolucizumab, Faricimab and Bevacizumab are all used.
• Intravitreal steroid implants (Ozurdex) — helpful in selected patients, particularly those who cannot return for frequent injections.
• Retinal laser (sector or pan-retinal) — for large non-perfusion areas or when new vessels develop. Treatment is targeted at preventing neovascular glaucoma.
• Surgery — rarely needed, for non-clearing vitreous haemorrhage or tractional changes.
• Control of underlying systemic disease — BP, diabetes and lipid management are essential to protect the other eye.

What to Expect from Treatment

Prevention & Self-Care

• Control blood pressure — this is the single most important step to protect the other eye
• Diabetes and cholesterol control
• Stop smoking
• Healthy weight, regular exercise
• Treat sleep apnoea if present
• If you have glaucoma, keep eye pressure controlled
• Yearly eye and systemic check-up

When to Come to Us Immediately

Sudden painless blurring in one eye, a new dark patch, or worsening of an old occlusion — come the same day. Early anti-VEGF treatment gives the best visual recovery.

Polypoidal Choroidal Vasculopathy, or PCV, is a disease of the choroidal blood vessels — the layer of vessels behind the retina. Abnormal branching vessels develop polyp-like dilations that leak fluid or bleed under the retina, damaging central vision. PCV is often mistaken for wet age-related macular degeneration (AMD), but it behaves differently, requires different imaging to confirm, and is treated somewhat differently.

What Happens Inside the Eye

The retina is nourished from behind by a thick layer of blood vessels called the choroid. In PCV, an abnormal branching network of vessels develops within the inner choroid, and at the tips of these branches, small bulbous dilations form — the “polyps”. These polyps are fragile. They leak fluid or break open and bleed, causing sudden distortion or loss of central vision.

Symptoms

• Sudden drop in central vision (especially after a bleed)
• Distorted or wavy lines (metamorphopsia)
• A dark patch in the centre of vision
• Often one eye first; the second eye is at increased risk later
• Vision may seem normal on the side, but reading and faces become difficult

Who Is at Risk?

• Age 50–65 (younger than typical AMD)
• Male gender (more often than female in Asian populations)
• Hypertension
• Smoking
• Asian / Indian ethnicity
• Sometimes a family history of macular disease

How PCV Differs from Typical Wet AMD

How We Diagnose PCV

• Dilated retinal examination — sub-RPE nodules can sometimes be seen as orange-red bumps
• OCT — sharp peaked retinal pigment epithelium detachment (PED), “double-layer sign”, subretinal fluid, sometimes a notch in the PED
• Indocyanine Green Angiography (ICGA) — the gold standard. Bright “hot-spots” mark the polyps, surrounded by a branching vascular network
• OCT-Angiography — non-invasively shows the branching vascular network
• Fluorescein angiography — to assess leakage and rule out classic CNV
• Fundus autofluorescence — supportive in selected cases

Treatment Options

• Intravitreal anti-VEGF injections — Aflibercept, Faricimab, Ranibizumab, Brolucizumab and Bevacizumab are all used. Most patients receive 3 monthly loading doses, then individualised maintenance.
• Photodynamic Therapy (PDT) — verteporfin is given by drip, then a special low-power laser is applied to the polyps. PDT is particularly effective at closing polyps in PCV.
• Combination therapy — anti-VEGF + PDT, often the best approach for large or resistant polyps.
• Observation — for asymptomatic, extrafoveal polyps that are not threatening vision.
• Submacular surgery — rarely, for massive submacular haemorrhage that does not clear with injections.

What to Expect from Treatment

• Stabilisation is the primary goal. Vision improvement is possible but less predictable than in pure wet AMD.
• Long-term follow-up is essential — recurrences are common, sometimes years later.
• The other eye must be monitored regularly — PCV often develops in the second eye over time.
• Bleeding episodes may recur. Catching them quickly limits damage.

Living with PCV

• Amsler grid daily for both eyes
• Strict blood pressure control
• Complete smoking cessation
• Sun protection (sunglasses outdoors)
• AREDS2 supplements if there are coexisting drusen
• Inform any doctor before starting new medication that may raise blood pressure or thin the blood

When to Come to Us Immediately

Sudden blurring, a new dark spot, or sudden distortion in either eye — these may signal a fresh bleed needing urgent attention. Come the same day.

Age-related Macular Degeneration (AMD) is a slow, age-related deterioration of the macula — the part of the retina responsible for sharp central vision. It is the leading cause of central vision loss after the age of 60. AMD does not cause complete blindness — the side (peripheral) vision is preserved — but it makes reading, recognising faces, driving and detailed work difficult.

The Two Types of AMD

AMD comes in two main forms, both starting from the same underlying ageing changes:

• Dry AMD — the more common form (about 85% of cases). The macula slowly thins and accumulates deposits called drusen. Vision loss is gradual.
• Wet AMD — less common (about 15% of cases) but causes most of the severe vision loss. Abnormal new blood vessels grow under the retina, leak fluid or blood, and rapidly damage the macula.

About 10–15% of patients with dry AMD will eventually develop wet AMD in one or both eyes. That is why anyone with dry AMD needs regular monitoring.

Symptoms

Early AMD

• Often no symptoms at all — the diagnosis is made on routine eye exam
• Mild blurring or difficulty reading small print
• Slightly slower adaptation when moving from bright light to dim light

Advanced dry AMD (geographic atrophy)

• A central blurred or dark area that gradually expands
• Faces become harder to recognise
• Reading becomes slow and tiring

Wet AMD

• Sudden distortion of straight lines
• A new dark spot or smudge in the centre of vision
• Sudden drop in central vision over days or weeks
• Difficulty reading or doing fine work that was easy a week before

Who Is at Risk?

• Age over 60 — the strongest risk factor
• Family history of AMD
• Smoking — doubles the risk; the most important modifiable factor
• High blood pressure and cardiovascular disease
• Long-term UV exposure without protection
• Poor diet, obesity, low intake of green leafy vegetables and fish
• Light iris colour (in some populations)

How We Diagnose AMD

• Dilated retinal examination — the first step; drusen, pigment changes and bleeds are usually visible
• OCT — the most important test. Shows drusen, fluid, atrophy and bleeds in cross-section
• OCT-Angiography — detects abnormal new vessels (CNV) without any dye injection
• Fundus autofluorescence (FAF) — maps areas of retinal cell loss
• Fluorescein angiography and ICG angiography — for difficult cases, especially when ruling out polypoidal disease (PCV)
• Amsler grid — for self-monitoring at home

Treatment

For Dry AMD

There is no medicine that fully cures dry AMD, but several steps slow the disease meaningfully:

• AREDS2 vitamins — a specific combination of antioxidants, lutein, zeaxanthin and zinc reduces the risk of progression to advanced AMD by about 25% in eligible patients.
• Diet rich in green leafy vegetables, fish, nuts and fruit.
• Quit smoking completely.
• Blood pressure and cardiovascular health.
• UV protection — sunglasses and a hat outdoors.
• Amsler grid weekly to catch conversion to wet AMD early.
• Newer therapies for geographic atrophy (complement inhibitors) are emerging — we will advise if you are a candidate.

For Wet AMD

• Intravitreal anti-VEGF injections — the cornerstone of wet AMD treatment. Drugs used include Ranibizumab, Aflibercept, Brolucizumab, Faricimab and Bevacizumab. The standard plan is three monthly loading injections, then maintenance based on OCT response.
• Photodynamic Therapy (PDT) — mainly for polypoidal lesions; sometimes combined with anti-VEGF.
• Submacular surgery — rarely needed, for very large submacular bleeds.

What to Expect from Treatment

• Wet AMD: Most patients stabilise; many gain some vision. Treatment is long-term — usually injections every 4–12 weeks, individualised.
• Dry AMD: AREDS2 and lifestyle slow progression. Most patients keep useful vision for many years if monitored.
• Both eyes need to be followed separately — AMD often develops in the second eye later.

Prevention & Self-Care

• Do not smoke (or stop, if you do)
• Eat green leafy vegetables, oily fish, fruits and nuts regularly
• Maintain healthy blood pressure and weight
• Wear UV-protective sunglasses outdoors
• Amsler grid weekly if you have early AMD or a family history
• Yearly dilated retinal exam after age 50; sooner if symptoms appear
• Discuss AREDS2 supplements with us if you have intermediate or advanced AMD in one eye

When to Come to Us Immediately

A new dark spot, new distortion of straight lines, a sudden drop in central vision — come the same day. Wet AMD treated within days has a far better outcome than wet AMD treated after weeks.

Diabetic Macular Edema, or DME, is the swelling of the macula — the central part of the retina responsible for sharp vision — due to fluid leaking out of damaged blood vessels in diabetes. It is the most common cause of vision loss in people with diabetes, and can occur at any stage of diabetic retinopathy, even mild.

What Happens Inside the Eye

In diabetes, tiny blood vessels in the retina become leaky. When the leak occurs at the macula, fluid accumulates between the layers of the retina — just like a sponge swelling with water. The macula thickens, the photoreceptors stop working normally, and the centre of your vision goes blurry or distorted. The longer this swelling lasts, the more permanent the damage.

DME vs. Diabetic Retinopathy — What’s the Difference?

Diabetic retinopathy is the umbrella term for all diabetes-related damage to the retinal blood vessels. DME is a specific complication — fluid leaking into the macula. DME can occur at any stage of diabetic retinopathy, even mild. Some patients with severe diabetic retinopathy never develop DME; others develop DME early. They are followed and treated as two related but separate conditions.

Symptoms

• Blurring of central vision — especially for reading or screens
• Distorted or wavy straight lines (metamorphopsia)
• Reduced contrast — colours look faded or “washed out”
• Difficulty reading small print, even with the right glasses
• A central blur or smudge that does not go away with blinking
• Peripheral (side) vision is usually preserved

Who Is at Risk?

• Long duration of diabetes
• HbA1c above 7.5%
• High blood pressure
• High cholesterol and triglycerides
• Kidney disease related to diabetes
• Pregnancy
• Recent cataract surgery (in diabetic eyes)

How We Diagnose DME

• Dilated retinal examination — the first step
• OCT (Optical Coherence Tomography) — the cornerstone test. A non-contact scan that measures the exact thickness of the macula and shows the fluid pockets
• OCT-Angiography — shows damage to the macular capillaries without dye
• Fluorescein angiography — when leakage patterns need to be mapped
• Fundus photography — to document hard exudates and bleeds over time

Types of DME We Treat

• Centre-involved DME (CI-DME) — fluid involves the foveal centre. Threatens vision more, treated more aggressively.
• Non-centre-involved DME — fluid present but the foveal centre is spared. May be observed or treated with focal laser.

Treatment Options

• Strict diabetic control — HbA1c, blood pressure, lipids and kidney function. Foundation of every treatment.
• Intravitreal anti-VEGF injections (Bevacizumab, Ranibizumab, Aflibercept, Brolucizumab, Faricimab) — first-line for centre-involving DME.
• Intravitreal steroids (Ozurdex implant, intravitreal triamcinolone) — for resistant cases, pseudophakic eyes, or when frequent visits are difficult.
• Focal or micropulse laser — for non-centre-involved DME, persistent leaks, or as add-on therapy.
• Vitrectomy surgery — rarely, for tractional DME or thick pre-macular membranes.

What to Expect from Treatment

• Most patients need multiple injections — typically 5–7 in the first year.
• Vision gains are gradual, often over 3–6 months.
• Strict diabetic control speeds recovery and reduces recurrence.
• Follow-up is lifelong — even when the eye is dry, the disease can return.
• The earlier we start treatment, the better the final vision.

Prevention & Self-Care

• HbA1c below 7% wherever safely possible
• Blood pressure below 140/90 mmHg
• LDL cholesterol controlled
• Quit smoking
• Regular dilated eye exams — annually for type 2 diabetes; within 5 years for type 1; each trimester in pregnancy
• Amsler grid at home for self-monitoring

When to Come to Us Immediately

Sudden drop in vision, new floaters, central distortion that has worsened, or a dark spot in the centre of your vision — come the same day.

Diabetic retinopathy is damage to the small blood vessels of the retina — the light-sensitive layer at the back of your eye — caused by long-standing high blood sugar. It is the most common eye complication of diabetes and the leading cause of preventable blindness in working-age adults in India. The good news: with timely diagnosis and modern treatment, severe vision loss is largely preventable.

What Happens Inside the Eye

Think of the retina as the film of your eye’s camera, nourished by a fine network of tiny blood vessels. In diabetes, these vessels gradually weaken. Some leak fluid and blood. Others close down completely, starving parts of the retina of oxygen. In response, the eye tries to grow new vessels, but these new vessels are fragile and harmful — they bleed easily, pull on the retina, and can cause blindness if untreated.

Who Is at Risk?

• Long duration of diabetes — the longer you have had diabetes, the higher the risk.
• Poor blood sugar control — particularly an HbA1c above 7.5%.
• High blood pressure and high cholesterol.
• Kidney disease related to diabetes.
• Pregnancy — diabetic retinopathy can worsen quickly.
• Smoking.
• Family history of diabetic eye disease.

Both type 1 and type 2 diabetes cause retinopathy, and so can gestational diabetes if it becomes chronic.

Symptoms — and Why You May Have None

In early stages, diabetic retinopathy causes no symptoms at all. As the disease progresses you may notice:

• Blurring of vision
• Difficulty reading small print
• Floaters — black spots, strings or cobwebs drifting across your sight
• Sudden dark patches or a “curtain” over part of your vision
• Distorted or wavy lines (when the macula is involved)
• Sudden, painless drop in vision (a vitreous haemorrhage)
• Poor night vision

The Stages of Diabetic Retinopathy

Non-Proliferative vs. Proliferative

• Non-Proliferative DR (NPDR) — the earlier stage. Vessels become leaky and fragile but no new abnormal vessels have grown yet. Sub-classified as mild, moderate or severe.
• Proliferative DR (PDR) — the advanced stage. Abnormal new vessels grow, which can bleed into the eye, cause scarring, retinal detachment, or a severe form of glaucoma. PDR is a sight-threatening emergency.

A Special Complication — Diabetic Macular Edema (DME)

At any stage of diabetic retinopathy — even mild — fluid can leak into the macula, the central part of the retina. This is called Diabetic Macular Edema and is the most common cause of vision loss in diabetics. See our separate article on DME for more.

How We Diagnose Diabetic Retinopathy

A complete diabetic eye check-up at Suraj Eye Institute takes 60–90 minutes and includes:

• Vision testing for distance and near
• Dilated retinal examination
• OCT — a non-contact scan that shows the layers of the macula and detects fluid
• OCT-Angiography — a dye-free scan of the retinal blood vessels
• Fundus photography to track changes over time
• Fluorescein angiography when needed
• Ultra-widefield imaging for a panoramic view of the peripheral retina

How Often Should I Be Checked?

Treatment Options

• Strict diabetes control is the foundation — no eye treatment works fully without controlled blood sugar, BP, lipids and kidney function.
• Intravitreal anti-VEGF injections (Bevacizumab, Ranibizumab, Aflibercept, Brolucizumab, Faricimab) — first-line for centre-involving DME and important in PDR. Most patients need 5–7 injections in year 1.
• Intravitreal steroids (Ozurdex implant, intravitreal triamcinolone) — for selected resistant cases.
• Laser treatment — Pan-Retinal Photocoagulation (PRP) for PDR; focal/grid laser for some DME cases; subthreshold/micropulse laser for selected macular disease.
• Vitrectomy surgery — for non-clearing vitreous haemorrhage, tractional retinal detachment involving the macula, and dense pre-macular haemorrhage.

What to Expect from Treatment

• Stabilisation, not always cure. The aim is to protect remaining vision and slow further damage.
• Recovery is gradual — vision gains, when they happen, occur over weeks to months.
• Most patients need ongoing follow-up for life, even after the eye stabilises.
• Skipping injections or follow-up is the commonest reason for vision loss in patients already under care.
• Treating one eye does not protect the other — both eyes are followed separately.

Prevention — What You Can Do

• HbA1c below 7% wherever safely possible
• Blood pressure below 140/90 mmHg (lower if advised)
• LDL cholesterol controlled
• Stop smoking completely
• Daily moderate activity — walking, swimming, yoga
• Annual dilated eye exam, even if you see perfectly well
• Amsler grid test at home (we will give you one)
• If you are planning a pregnancy, see us before conception
• Take your medicines regularly — including injections of anti-VEGF if prescribed

When to Come to Us Immediately